{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T13:59:50Z","timestamp":1787061590496,"version":"build-2736575974"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100009655","name":"Sunovion Pharmaceuticals Inc.","doi-asserted-by":"publisher","award":["SP0040239"],"award-info":[{"award-number":["SP0040239"]}],"id":[{"id":"10.13039\/100009655","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Weisman Foundation"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.schres.2018.04.006","type":"journal-article","created":{"date-parts":[[2018,5,2]],"date-time":"2018-05-02T14:47:40Z","timestamp":1525272460000},"page":"203-213","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Identifying the genetic risk factors for treatment response to lurasidone by genome-wide association study: A meta-analysis of samples from three independent clinical trials"],"prefix":"10.1016","volume":"199","author":[{"given":"Jiang","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antony","family":"Loebel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4901-8845","authenticated-orcid":false,"given":"Herbert Y.","family":"Meltzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.schres.2018.04.006_bb0005","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/nn1212","article-title":"Stability of dendritic spines and synaptic contacts is controlled by alpha N-catenin","volume":"7","author":"Abe","year":"2004","journal-title":"Nat. Neurosci."},{"issue":"4","key":"10.1016\/j.schres.2018.04.006_bb0010","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/j.celrep.2014.07.026","article-title":"Dysregulated expression of neuregulin-1 by cortical pyramidal neurons disrupts synaptic plasticity","volume":"8","author":"Agarwal","year":"2014","journal-title":"Cell Rep."},{"issue":"8","key":"10.1016\/j.schres.2018.04.006_bb0020","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/sj.mp.4002009","article-title":"Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research","volume":"12","author":"Arranz","year":"2007","journal-title":"Mol. Psychiatry"},{"issue":"2","key":"10.1016\/j.schres.2018.04.006_bb0025","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ajhg.2008.07.010","article-title":"Maternally inherited Birk Barel mental retardation dysmorphism syndrome caused by a mutation in the genomically imprinted potassium channel KCNK9","volume":"83","author":"Barel","year":"2008","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.schres.2018.04.006_bb0030","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.neuroscience.2014.05.004","article-title":"Reduced CHRNA7 expression in C3H mice is associated with increases in hippocampal parvalbumin and glutamate decarboxylase-67 (GAD67) as well as altered levels of GABA(A) receptor subunits","volume":"273","author":"Bates","year":"2014","journal-title":"Neuroscience"},{"issue":"30","key":"10.1016\/j.schres.2018.04.006_bb0035","doi-asserted-by":"crossref","first-page":"6693","DOI":"10.1523\/JNEUROSCI.1408-04.2004","article-title":"Motoneurons express heteromeric TWIK-related acid-sensitive K+ (TASK) channels containing TASK-1 (KCNK3) and TASK-3 (KCNK9) subunits","volume":"24","author":"Berg","year":"2004","journal-title":"The Journal of Neuroscience: The Official Journal of the Society for Neuroscience"},{"key":"10.1016\/j.schres.2018.04.006_bb0040","series-title":"Pharmacogenomics","first-page":"3","article-title":"Pharmacogenomics: historical perspective and current status","author":"Charlab","year":"2013"},{"issue":"7","key":"10.1016\/j.schres.2018.04.006_bb0045","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/nrg.2016.27","article-title":"Developing and evaluating polygenic risk prediction models for stratified disease prevention","volume":"17","author":"Chatterjee","year":"2016","journal-title":"Nat. Rev. Genet."},{"issue":"11","key":"10.1016\/j.schres.2018.04.006_bb0050","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1176\/appi.ajp.2016.16010025","article-title":"Pathological basis for deficient excitatory drive to cortical parvalbumin interneurons in schizophrenia","volume":"173","author":"Chung","year":"2016","journal-title":"Am. J. Psychiatry"},{"issue":"6","key":"10.1016\/j.schres.2018.04.006_bb0055","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/nrg2579","article-title":"Detecting gene-gene interactions that underlie human diseases","volume":"10","author":"Cordell","year":"2009","journal-title":"Nat. Rev. Genet."},{"issue":"13","key":"10.1016\/j.schres.2018.04.006_bb0060","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1038\/npp.2017.123","article-title":"Cognitive characterization of schizophrenia risk variants involved in synaptic transmission: evidence of CACNA1C's role in working memory","volume":"42","author":"Cosgrove","year":"2017","journal-title":"Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology"},{"issue":"3","key":"10.1016\/j.schres.2018.04.006_bb0065","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1003348","article-title":"Power and predictive accuracy of polygenic risk scores","volume":"9","author":"Dudbridge","year":"2013","journal-title":"PLoS Genet."},{"issue":"12","key":"10.1016\/j.schres.2018.04.006_bb0070","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1176\/appi.ajp.2012.12020218","article-title":"Genome-wide association study of clinical dimensions of schizophrenia: polygenic effect on disorganized symptoms","volume":"169","author":"Fanous","year":"2012","journal-title":"Am. J. Psychiatry"},{"issue":"4","key":"10.1016\/j.schres.2018.04.006_bb0075","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1007\/s00429-014-0766-0","article-title":"Tomosyn-2 is required for normal motor performance in mice and sustains neurotransmission at motor endplates","volume":"220","author":"Geerts","year":"2015","journal-title":"Brain Struct. Funct."},{"issue":"5","key":"10.1016\/j.schres.2018.04.006_bb0080","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1004383","article-title":"Bayesian test for colocalisation between pairs of genetic association studies using summary statistics","volume":"10","author":"Giambartolomei","year":"2014","journal-title":"PLoS Genet."},{"issue":"4","key":"10.1016\/j.schres.2018.04.006_bb0085","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1124\/pr.57.4.12","article-title":"International Union of Pharmacology. LV. Nomenclature and molecular relationships of two-P potassium channels","volume":"57","author":"Goldstein","year":"2005","journal-title":"Pharmacol. Rev."},{"issue":"5","key":"10.1016\/j.schres.2018.04.006_bb0090","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/nrg2544","article-title":"Validating, augmenting and refining genome-wide association signals","volume":"10","author":"Ioannidis","year":"2009","journal-title":"Nat. Rev. Genet."},{"issue":"1","key":"10.1016\/j.schres.2018.04.006_bb0095","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1124\/jpet.110.167346","article-title":"Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity","volume":"334","author":"Ishibashi","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"13","key":"10.1016\/j.schres.2018.04.006_bb0100","doi-asserted-by":"crossref","first-page":"9340","DOI":"10.1074\/jbc.275.13.9340","article-title":"TASK-3, a new member of the tandem pore K(+) channel family","volume":"275","author":"Kim","year":"2000","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.schres.2018.04.006_bb0105","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/mp.2017.111","article-title":"Comparative genomic evidence for the involvement of schizophrenia risk genes in antipsychotic effects","volume":"23","author":"Kim","year":"2018","journal-title":"Mol. Psychiatry"},{"issue":"7","key":"10.1016\/j.schres.2018.04.006_bb0110","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1093\/hmg\/ddu614","article-title":"Homozygous mutation of STXBP5L explains an autosomal recessive infantile-onset neurodegenerative disorder","volume":"24","author":"Kumar","year":"2015","journal-title":"Hum. Mol. Genet."},{"issue":"8","key":"10.1016\/j.schres.2018.04.006_bb0115","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1038\/mp.2008.56","article-title":"Association of the NPAS3 gene and five other loci with response to the antipsychotic iloperidone identified in a whole genome association study","volume":"14","author":"Lavedan","year":"2009","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.schres.2018.04.006_bb0120","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2015.97","article-title":"A double amino-acid change in the HLA-A peptide-binding groove is associated with response to psychotropic treatment in patients with schizophrenia","volume":"5","author":"Le Clerc","year":"2015","journal-title":"Transl. Psychiatry"},{"issue":"4","key":"10.1016\/j.schres.2018.04.006_bb0125","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1004219","article-title":"MAGMA: generalized gene-set analysis of GWAS data","volume":"11","author":"de Leeuw","year":"2015","journal-title":"PLoS Comput. Biol."},{"issue":"2","key":"10.1016\/j.schres.2018.04.006_bb0130","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.schres.2014.08.018","article-title":"A genetic locus in 7p12. 2 associated with treatment resistant schizophrenia","volume":"159","author":"Li","year":"2014","journal-title":"Schizophr. Res."},{"issue":"1","key":"10.1016\/j.schres.2018.04.006_bb0140","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1097\/FPC.0000000000000250","article-title":"Genome-wide association study of paliperidone efficacy","volume":"27","author":"Li","year":"2017","journal-title":"Pharmacogenet. Genomics"},{"key":"10.1016\/j.schres.2018.04.006_bb0135","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.schres.2017.04.009","article-title":"Genetic predictors of antipsychotic response to lurasidone identified in a genome wide association study and by schizophrenia risk genes","volume":"192","author":"Li","year":"2018","journal-title":"Schizophr. Res."},{"issue":"1","key":"10.1016\/j.schres.2018.04.006_bb0145","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1124\/jpet.108.142083","article-title":"K+ channel TASK-1 knockout mice show enhanced sensitivities to ataxic and hypnotic effects of GABA(A) receptor ligands","volume":"327","author":"Linden","year":"2008","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"1","key":"10.1016\/j.schres.2018.04.006_bb0150","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.schres.2013.01.009","article-title":"Efficacy and safety of lurasidone 80\u202fmg\/day and 160\u202fmg\/day in the treatment of schizophrenia: a randomized, double-blind, placebo-and active-controlled trial","volume":"145","author":"Loebel","year":"2013","journal-title":"Schizophr. Res."},{"issue":"1","key":"10.1016\/j.schres.2018.04.006_bb0155","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.schres.2013.03.013","article-title":"Effectiveness of lurasidone vs. quetiapine XR for relapse prevention in schizophrenia: a 12-month, double-blind, noninferiority study","volume":"147","author":"Loebel","year":"2013","journal-title":"Schizophr. Res."},{"issue":"3","key":"10.1016\/j.schres.2018.04.006_bb0160","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/npp.2010.193","article-title":"Genome-wide pharmacogenomic study of neurocognition as an indicator of antipsychotic treatment response in schizophrenia","volume":"36","author":"McClay","year":"2011","journal-title":"Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.schres.2018.04.006_bb0165","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/mp.2009.89","article-title":"Genome-wide pharmacogenomic analysis of response to treatment with antipsychotics","volume":"16","author":"McClay","year":"2011","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.schres.2018.04.006_bb0170","series-title":"Current Antipsychotics","first-page":"87","article-title":"Serotonergic mechanisms as targets for existing and novel antipsychotics","author":"Meltzer","year":"2012"},{"issue":"9","key":"10.1016\/j.schres.2018.04.006_bb0175","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1176\/appi.ajp.2011.10060907","article-title":"Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo-and olanzapine-controlled study","volume":"168","author":"Meltzer","year":"2011","journal-title":"Am. J. Psychiatr."},{"issue":"2\u20133","key":"10.1016\/j.schres.2018.04.006_bb0180","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s00213-010-2137-8","article-title":"The role of serotonin in the NMDA receptor antagonist models of psychosis and cognitive impairment","volume":"213","author":"Meltzer","year":"2011","journal-title":"Psychopharmacology"},{"issue":"2","key":"10.1016\/j.schres.2018.04.006_bb0185","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.molbrainres.2005.06.006","article-title":"Differential modulation of gene expression in the NMDA postsynaptic density of schizophrenic and control smokers","volume":"139","author":"Mexal","year":"2005","journal-title":"Brain Res. Mol. Brain Res."},{"issue":"11","key":"10.1016\/j.schres.2018.04.006_bb0190","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1517\/13543780903286388","article-title":"Lurasidone: a new drug in development for schizophrenia","volume":"18","author":"Meyer","year":"2009","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"1","key":"10.1016\/j.schres.2018.04.006_bb0195","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1017\/thg.2014.79","article-title":"VEGAS2: software for more flexible gene-based testing","volume":"18","author":"Mishra","year":"2015","journal-title":"Twin Research and Human Genetics: The Official Journal of the International Society for Twin Studies"},{"issue":"5","key":"10.1016\/j.schres.2018.04.006_bb0200","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.jpsychires.2013.01.020","article-title":"Lurasidone for the treatment of acutely psychotic patients with schizophrenia: a 6-week, randomized, placebo-controlled study","volume":"47","author":"Nasrallah","year":"2013","journal-title":"J. Psychiatr. Res."},{"issue":"7","key":"10.1016\/j.schres.2018.04.006_bb0205","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1038\/ejhg.2008.264","article-title":"Pharmacogenetics of antipsychotic response in the CATIE trial: a candidate gene analysis","volume":"17","author":"Need","year":"2009","journal-title":"Eur. J. Hum. Genet."},{"issue":"5","key":"10.1016\/j.schres.2018.04.006_bb0210","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/nmeth.1938","article-title":"Detecting overlapping protein complexes in protein-protein interaction networks","volume":"9","author":"Nepusz","year":"2012","journal-title":"Nat. Methods"},{"issue":"2","key":"10.1016\/j.schres.2018.04.006_bb0215","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1038\/mp.2017.37","article-title":"The schizophrenia- and autism-associated gene, transcription factor 4 regulates the columnar distribution of layer 2\/3 prefrontal pyramidal neurons in an activity-dependent manner","volume":"23","author":"Page","year":"2018","journal-title":"Mol. Psychiatry"},{"issue":"41","key":"10.1016\/j.schres.2018.04.006_bb0220","doi-asserted-by":"crossref","first-page":"17546","DOI":"10.1073\/pnas.0907228106","article-title":"An unexpected role for TASK-3 potassium channels in network oscillations with implications for sleep mechanisms and anesthetic action","volume":"106","author":"Pang","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"3","key":"10.1016\/j.schres.2018.04.006_bb0225","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/ng908","article-title":"Deletion in Catna2, encoding alpha N-catenin, causes cerebellar and hippocampal lamination defects and impaired startle modulation","volume":"31","author":"Park","year":"2002","journal-title":"Nat. Genet."},{"issue":"7487","key":"10.1016\/j.schres.2018.04.006_bb0230","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/nature12975","article-title":"A polygenic burden of rare disruptive mutations in schizophrenia","volume":"506","author":"Purcell","year":"2014","journal-title":"Nature"},{"issue":"7510","key":"10.1016\/j.schres.2018.04.006_bb0015","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/nature13595","article-title":"Biological insights from 108 schizophrenia-associated genetic loci","volume":"511","author":"Ripke","year":"2014","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.schres.2018.04.006_bb0235","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/S2215-0366(15)00553-2","article-title":"Polygenic overlap between schizophrenia risk and antipsychotic response: a genomic medicine approach","volume":"3","author":"Ruderfer","year":"2016","journal-title":"The Lancet. Psychiatry"},{"issue":"2","key":"10.1016\/j.schres.2018.04.006_bb0240","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/tpj.2015.90","article-title":"The GRM7 gene, early response to risperidone, and schizophrenia: a genome-wide association study and a confirmatory pharmacogenetic analysis","volume":"17","author":"Sacchetti","year":"2017","journal-title":"Pharmacogenomics J."},{"issue":"1","key":"10.1016\/j.schres.2018.04.006_bb0245","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s40263-012-0026-x","article-title":"Lurasidone","volume":"27","author":"Sanford","year":"2013","journal-title":"CNS Drugs"},{"issue":"1\u20132","key":"10.1016\/j.schres.2018.04.006_bb0250","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.molbrainres.2004.12.025","article-title":"Expression of Catenin family members CTNNA1, CTNNA2, CTNNB1 and JUP in the primate prefrontal cortex and hippocampus","volume":"135","author":"Smith","year":"2005","journal-title":"Brain Res. Mol. Brain Res."},{"key":"10.1016\/j.schres.2018.04.006_bb0255","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2016.10","article-title":"Antipsychotic pharmacogenomics in first episode psychosis: a role for glutamate genes","volume":"6","author":"Stevenson","year":"2016","journal-title":"Transl. Psychiatry"},{"issue":"12","key":"10.1016\/j.schres.2018.04.006_bb0260","doi-asserted-by":"crossref","DOI":"10.1038\/mp.2008.74","article-title":"Genomewide association for schizophrenia in the CATIE study: results of stage 1","volume":"14","author":"Sullivan","year":"2009","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.schres.2018.04.006_bb0265","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2011.42","article-title":"Meta-analysis of genome-wide association studies identifies common variants in CTNNA2 associated with excitement-seeking","volume":"1","author":"Terracciano","year":"2011","journal-title":"Transl. Psychiatry"},{"issue":"6","key":"10.1016\/j.schres.2018.04.006_bb0270","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/j.celrep.2014.02.005","article-title":"HITS-CLIP and integrative modeling define the Rbfox splicing-regulatory network linked to brain development and autism","volume":"6","author":"Weyn-Vanhentenryck","year":"2014","journal-title":"Cell Rep."},{"issue":"17","key":"10.1016\/j.schres.2018.04.006_bb0275","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1093\/bioinformatics\/btq340","article-title":"METAL: fast and efficient meta-analysis of genomewide association scans","volume":"26","author":"Willer","year":"2010","journal-title":"Bioinformatics"},{"issue":"5","key":"10.1016\/j.schres.2018.04.006_bb0280","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1093\/schbul\/sbx007","article-title":"Polygenic risk score for schizophrenia and treatment-resistant schizophrenia","volume":"43","author":"Wimberley","year":"2017","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2018.04.006_bb0285","first-page":"1","article-title":"Genetic study of neuregulin 1 and receptor tyrosine-protein kinase erbB-4 in tardive dyskinesia","author":"Zai","year":"2017","journal-title":"The World Journal of Biological Psychiatry: The Official Journal of the World Federation of Societies of Biological Psychiatry"},{"key":"10.1016\/j.schres.2018.04.006_bb0290","article-title":"Olanzapine prevents the PCP-induced reduction in the neurite outgrowth of prefrontal cortical neurons via NRG1","volume":"6","author":"Zhang","year":"2016","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.schres.2018.04.006_bb0295","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/nmeth.3249","article-title":"Targeted exploration and analysis of large cross-platform human transcriptomic compendia","volume":"12","author":"Zhu","year":"2015","journal-title":"Nat. Methods"}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996418301956?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996418301956?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,24]],"date-time":"2019-09-24T08:19:01Z","timestamp":1569313141000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996418301956"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":59,"alternative-id":["S0920996418301956"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2018.04.006","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identifying the genetic risk factors for treatment response to lurasidone by genome-wide association study: A meta-analysis of samples from three independent clinical trials","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2018.04.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}